Monte Rosa Therapeutics, Inc. GLUE Financing Cash Flow
Financing Cash Flow at other companies
Other financials
Where this comes from
Reported directly by Monte Rosa Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInFinancingActivities.
The official record: Monte Rosa Therapeutics, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Monte Rosa Therapeutics, Inc.'s financing cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Monte Rosa Therapeutics, Inc.'s financing cash flow?
- Monte Rosa Therapeutics, Inc. (GLUE) reported financing cash flow of $328.34M in Q1 2026.
- How has Monte Rosa Therapeutics, Inc.'s financing cash flow changed year-over-year?
- Monte Rosa Therapeutics, Inc.'s financing cash flow increased by 2345150.0% year-over-year, from $14K to $328.34M.
- What is the long-term trend for Monte Rosa Therapeutics, Inc.'s financing cash flow?
- Over 4 years (2021 to 2025), Monte Rosa Therapeutics, Inc.'s financing cash flow has grown at a -46.8% compound annual growth rate (CAGR), from $377.7M to $30.35M.
- What does financing cash flow mean?
- Total net cash provided by or used in financing activities — debt issuance/repayment, equity transactions, and dividend payments.